BR112015024760A2 - oligonucleotídeo beta modificado para uso em um método de prevenção e/ou tratamento de uma doença oftálmica - Google Patents
oligonucleotídeo beta modificado para uso em um método de prevenção e/ou tratamento de uma doença oftálmicaInfo
- Publication number
- BR112015024760A2 BR112015024760A2 BR112015024760A BR112015024760A BR112015024760A2 BR 112015024760 A2 BR112015024760 A2 BR 112015024760A2 BR 112015024760 A BR112015024760 A BR 112015024760A BR 112015024760 A BR112015024760 A BR 112015024760A BR 112015024760 A2 BR112015024760 A2 BR 112015024760A2
- Authority
- BR
- Brazil
- Prior art keywords
- tgf
- oligonucleotide
- macular degeneration
- nucleotides
- modified
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
abstract the invention refers to an oligonucleotide consisting of 10 to 20 nucleotides of selected regions of the tgf-beta1, tgf-beta2 or tgf-beta3 nucleic acid sequence, which comprises modified nucleotides such as lna, ena, polyalkylene oxide-, 2'-fluoro, 2'-o- methoxy and/or 2'-o-methyl modified nucleotides. the invention further relates to pharmaceutical compositions comprising such oligonucleotide, wherein the composition or the oligonucleotide is used in a method for the prevention and/or treatment of glaucoma, posterior capsular opacification, dry eye, marfan or loeys- dietz syndrome, riboblastoma, choroidcarcinoma, macular degeneration, such as age- related macular degeneration, diabetic macular endma, or cataract. ------------------------------------------------------------------------------------------ tradução do resumo resumo patente de invenção: "oligonucleotídeo beta modificado para uso em um método de prevenção e/ou tratamen-to de uma doença oftálmica". a invenção se refere a um oligonucleotídeo consistindo de 10 a 20 nucleotídeos de regiões selecionadas da sequência de nucleo-tídeo de tgf-beta1, tgf-beta2 ou tgf-beta3, que compreende nu-cleotídeo modificados, tais como nucleotídeos modificados de lna, ena, óxido de polialquileno-, 2'-fluoro, 2'-o-meóxi e/ou 2'-o-metil. a invenção se relaciona adicionalmente a composições farmacêuticas compreendendo tal oligonucleotídeo, no qual a composição ou o oligo-nucleotídeo é usado em um método para a prevenção e/ou tratamento de glaucoma, opacificação capsular posterior, olho seco, síndrome de marfan ou de loeys-dietz, riboblastoma, coroidocarcinoma, degenera-ção macular, tal como degeneração macular relacionada à idade, edema macular diabético, ou catarata.
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13161474 | 2013-03-27 | ||
| EP13161474.5 | 2013-03-27 | ||
| EP13173078.0 | 2013-06-20 | ||
| EP13173078 | 2013-06-20 | ||
| EP13199826.2 | 2013-12-30 | ||
| EP13199831.2 | 2013-12-30 | ||
| EP13199826 | 2013-12-30 | ||
| EP13199831 | 2013-12-30 | ||
| EP13199838.7 | 2013-12-30 | ||
| EP13199838 | 2013-12-30 | ||
| PCT/EP2014/056222 WO2014154836A2 (en) | 2013-03-27 | 2014-03-27 | Modified tgf-beta oligonucleotide for use in a method of preventing and/or treating an ophthalmic disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112015024760A2 true BR112015024760A2 (pt) | 2017-10-24 |
| BR112015024760B1 BR112015024760B1 (pt) | 2021-09-21 |
| BR112015024760B8 BR112015024760B8 (pt) | 2022-06-21 |
Family
ID=50440642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015024760A BR112015024760B8 (pt) | 2013-03-27 | 2014-03-27 | Oligonucleotídeo antissenso, composição farmacêutica e uso dos mesmos na prevenção e/ou tratamento de uma doença oftálmica |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US9688988B2 (pt) |
| EP (1) | EP2978846B1 (pt) |
| JP (1) | JP6475226B2 (pt) |
| KR (1) | KR102094572B1 (pt) |
| CN (1) | CN105283551B (pt) |
| BR (1) | BR112015024760B8 (pt) |
| CA (1) | CA2908101C (pt) |
| DK (1) | DK2978846T3 (pt) |
| EA (1) | EA201591594A1 (pt) |
| ES (1) | ES2784213T3 (pt) |
| HK (1) | HK1221254A1 (pt) |
| HU (1) | HUE049246T2 (pt) |
| LT (1) | LT2978846T (pt) |
| PL (1) | PL2978846T3 (pt) |
| PT (1) | PT2978846T (pt) |
| SI (1) | SI2978846T1 (pt) |
| WO (1) | WO2014154836A2 (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018009895A1 (en) * | 2016-07-08 | 2018-01-11 | Autotelic Llc | Methods for trabedersen dosing by auc |
| WO2018087359A1 (en) * | 2016-11-11 | 2018-05-17 | Isarna Therapeutics Gmbh | Tgf-beta oligonucleotide for use in treatment of ophthalmic diseases |
| US11771703B2 (en) | 2017-03-17 | 2023-10-03 | The Johns Hopkins University | Targeted epigenetic therapy against distal regulatory element of TGFβ2 expression |
| CN113018508A (zh) * | 2021-03-15 | 2021-06-25 | 西安交通大学医学院第一附属医院 | 一种表面修饰的人工晶状体及其制备方法 |
| KR102549208B1 (ko) * | 2021-04-08 | 2023-06-30 | 연세대학교 산학협력단 | 심혈관 질환과 관련된 LncRNA 및 이의 용도 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994025588A2 (en) | 1993-04-30 | 1994-11-10 | Biognostik Gesellschaft für Biomolekulare Diagnostik mbH | ANTISENSE-OLIGONUCLEOTIDES FOR THE TREATMENT OF IMMUNOSUPPRESSIVE EFFECTS OF TRANSFORMING GROWTH FACTOR-β (TGF-β) |
| EP1008649B1 (en) | 1993-04-30 | 2003-03-26 | Biognostik Gesellschaft für biomolekulare Diagnostik mbH | Antisense-oligonucleotides for the treatment of immuno-suppressive effects of transforming growth factor-b2(TGF-b2) |
| US20040006030A1 (en) | 2002-07-02 | 2004-01-08 | Isis Pharmaceuticals Inc. | Antisense modulation of TGF-beta 2 expression |
| EP1568383A3 (en) | 2004-02-27 | 2005-11-16 | Antisense Pharma GmbH | Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metastases in cancer treatment |
| JP5650367B2 (ja) * | 2004-02-27 | 2015-01-07 | アンティセンス ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 医薬組成物 |
| EP1935428A1 (en) | 2006-12-22 | 2008-06-25 | Antisense Pharma GmbH | Oligonucleotide-polymer conjugates |
| JP2013531981A (ja) * | 2010-06-11 | 2013-08-15 | アンチセンス・ファーマ・ゲーエムベーハー | 選択的オリゴヌクレオチド修飾の方法 |
| EP2453017A1 (en) * | 2010-11-12 | 2012-05-16 | Antisense Pharma GmbH | Oligonucleotides for use in prophylaxis and/or treatment of TGF-beta1 and TGF-beta2, TGF-beta2 and TGF-beta3, TGF-beta1 and TGF-beta3, or TGF-beta1, TGF-beta2, and TGF-beta3 mRNA overexpressing diseases |
| US10058623B2 (en) | 2012-05-16 | 2018-08-28 | Translate Bio Ma, Inc. | Compositions and methods for modulating UTRN expression |
-
2014
- 2014-03-27 HU HUE14715563A patent/HUE049246T2/hu unknown
- 2014-03-27 DK DK14715563.4T patent/DK2978846T3/da active
- 2014-03-27 CA CA2908101A patent/CA2908101C/en active Active
- 2014-03-27 CN CN201480030396.2A patent/CN105283551B/zh active Active
- 2014-03-27 US US14/779,930 patent/US9688988B2/en active Active
- 2014-03-27 BR BR112015024760A patent/BR112015024760B8/pt active IP Right Grant
- 2014-03-27 WO PCT/EP2014/056222 patent/WO2014154836A2/en active Application Filing
- 2014-03-27 ES ES14715563T patent/ES2784213T3/es active Active
- 2014-03-27 SI SI201431537T patent/SI2978846T1/sl unknown
- 2014-03-27 EA EA201591594A patent/EA201591594A1/ru unknown
- 2014-03-27 PT PT147155634T patent/PT2978846T/pt unknown
- 2014-03-27 JP JP2016504683A patent/JP6475226B2/ja active Active
- 2014-03-27 KR KR1020157030781A patent/KR102094572B1/ko active IP Right Grant
- 2014-03-27 EP EP14715563.4A patent/EP2978846B1/en active Active
- 2014-03-27 LT LTEP14715563.4T patent/LT2978846T/lt unknown
- 2014-03-27 PL PL14715563T patent/PL2978846T3/pl unknown
-
2016
- 2016-08-03 HK HK16109277.7A patent/HK1221254A1/zh unknown
-
2017
- 2017-05-12 US US15/593,764 patent/US10125368B2/en active Active
-
2018
- 2018-11-09 US US16/185,822 patent/US20190144865A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR102094572B1 (ko) | 2020-03-30 |
| US9688988B2 (en) | 2017-06-27 |
| US10125368B2 (en) | 2018-11-13 |
| PL2978846T4 (pl) | 2020-09-21 |
| EA201591594A1 (ru) | 2016-05-31 |
| CA2908101A1 (en) | 2014-10-02 |
| EP2978846B1 (en) | 2019-12-25 |
| EP2978846A2 (en) | 2016-02-03 |
| BR112015024760B1 (pt) | 2021-09-21 |
| JP6475226B2 (ja) | 2019-02-27 |
| ES2784213T3 (es) | 2020-09-23 |
| HK1221254A1 (zh) | 2017-05-26 |
| US20190144865A1 (en) | 2019-05-16 |
| LT2978846T (lt) | 2020-04-10 |
| SI2978846T1 (sl) | 2020-07-31 |
| CN105283551A (zh) | 2016-01-27 |
| WO2014154836A2 (en) | 2014-10-02 |
| DK2978846T3 (da) | 2020-04-06 |
| WO2014154836A3 (en) | 2014-11-20 |
| BR112015024760B8 (pt) | 2022-06-21 |
| CA2908101C (en) | 2021-06-22 |
| HUE049246T2 (hu) | 2020-09-28 |
| PT2978846T (pt) | 2020-04-21 |
| JP2016519573A (ja) | 2016-07-07 |
| US20160040167A1 (en) | 2016-02-11 |
| KR20150140702A (ko) | 2015-12-16 |
| US20170314025A1 (en) | 2017-11-02 |
| PL2978846T3 (pl) | 2020-09-21 |
| CN105283551B (zh) | 2018-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015024729A8 (pt) | oligonucleotídeos tgf-beta2 modificados | |
| MX2024005652A (es) | Agentes de acido ribonucleico (arn) de cadena doble modificados. | |
| BR112015024760A2 (pt) | oligonucleotídeo beta modificado para uso em um método de prevenção e/ou tratamento de uma doença oftálmica | |
| MX2023010958A (es) | Agentes de arn modificados con efecto reducido fuera de la diana. | |
| EA201490993A1 (ru) | МОДИФИЦИРОВАННЫЕ СРЕДСТВА РНКи | |
| CO2018001484A2 (es) | Oligonucleótidos quiralmente controlados que comprenden azúcares modificados y ligaciones internucleotídicos modificadas y estereocontroladas, omposiciones y métodos de los mismos | |
| MX2010009195A (es) | Rnas ultrapequeños como antagonistas del receptor tipo toll-3. | |
| CR20190212A (es) | 1,2,4-triazolonas 2,4,5-trisustituidas | |
| BR112013018920A2 (pt) | composições de nanopartículas, formulações destas e seus usos | |
| MX2021006745A (es) | Constructos de iarn modificados quimicamente y usos de estos. | |
| BR112017002221A2 (pt) | 2-(morfolin-4-il)-1,7-naftiridinas | |
| BR112015024764A2 (pt) | oligonucleotídeos de tgf-beta modificados | |
| UA118649C2 (uk) | ДВОЛАНЦЮГОВИЙ ЗАСІБ ДЛЯ PHKі ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ДЛЯ ІНГІБУВАННЯ ЕКСПРЕСІЇ ТРАНСТИРЕТИНУ (TTR) | |
| WO2014022739A3 (en) | Modified rnai agents | |
| PE20211393A1 (es) | COMPOSICIONES DE ARNi CONTRA EL COMPONENTE C5 DEL COMPLEMENTO Y METODOS PARA SU USO | |
| CL2013003105A1 (es) | Compuestos de microarn que comprende secuencias de nucleósidos modificados, inhibidores de mir-21; usos de los compuestos para modular la actividad de mir -21 y para preparar un medicamento para tratar fibrosis, heridas o cancer | |
| AR084319A1 (es) | INHIBIDORES DE microARN (miARN O miR) QUE COMPRENDEN NUCLEOTIDOS BLOQUEADOS | |
| MX2015008697A (es) | Tratamiento contra la degeneración macular relacionada con la edad. | |
| PE20191351A1 (es) | Tratamiento aav de la enfermedad de huntington | |
| BR112016013148A2 (pt) | "composições de rnai de componente do complemento e métodos de utilização das mesmas | |
| PE20142404A1 (es) | Compuestos de microarn y metodos de modulacion de la actividad de mir-21 | |
| AR102777A1 (es) | COMPOSICIONES DE ARNi CONTRA TMPRSS6 Y MÉTODOS PARA SU USO | |
| BR112015006929A2 (pt) | sistemas de distribuição de droga biodegradável para liberação sustentada de proteínas | |
| BR112017018329A2 (pt) | composição para prevenir ou tratar calcificação de válvula, contendo inibidor de dpp-4 | |
| AR123679A1 (es) | COMPOSICIONES DE ARNi CONTRA EL GEN SNCA Y MÉTODOS DE USO DE LAS MISMAS PARA TRATAR O PREVENIR ENFERMEDADES NEURODEGENERATIVAS ASOCIADAS CON SNCA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C12N 15/113 , A61K 31/713 , C07H 21/02 , A61P 27/02 , A61P 35/00 Ipc: C12N 15/113 (2010.01), C07H 21/02 (2006.01), A61K |
|
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/03/2014, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REF. RPI 2646 DE 21/09/2021 QUANTO AO INVENTOR POR ERRO MATERIAL DO USUARIO. |